LOS ANGELES, April 3 (Reuters) - Amgen Inc. (AMGN.O: Quote, Profile, Research) said full results from a pivotal-stage trial of its experimental cancer drug panitumumab show that the drug slows tumor growth in patients with advanced colon cancer who had failed to respond to chemotherapy.
